Guess which ASX biotech stock is rocketing 28% on 'extremely encouraging' Alzheimer's data

Alzheimer's Disease accounts for 60% to 70% of all cases of dementia.

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Argenica Therapeutics shares are up 28% in afternoon trade
  • The ASX biotech stock reported promising preclinical results to treat Alzheimer’s Disease
  • The global Alzheimer’s Disease therapeutics market size was valued at US$4 billion in 2021

ASX biotech stock Argenica Therapeutics Ltd (ASX: AGN) is off to the races today.

Shares in the biotechnology company closed yesterday trading at 41 cents and are currently swapping hands for 52 cents apiece, up 28.4%.

Here's what's piquing ASX investor interest today.

What did the ASX biotech stock report?

Argenica Therapeutics shares are rocketing after the ASX biotech stock reported promising results with its lead neuroprotective peptide candidate, ARG-007, in an in vitro preclinical study.

According to the company's release, the preclinical results indicated ARG-007 "significantly inhibits the aggregation of human recombinant Amyloid-Beta (Abeta) in a cell-free Abeta aggregation assay model".

That could prove to be great news for patients suffering from Alzheimer's Disease, which accounts for 60% to 70% of all cases of dementia. Abeta aggregation is believed to be one of the main causes of Alzheimer's, with the Abeta accumulation in senile plaques causing memory loss and confusion.

Argenica reported that Abeta aggregation was reduced by more than 50% compared to vehicle controls 16 hours following a 25 µM dose of ARG-007.

Commenting on the results sending the ASX biotech stock soaring today, Argenica managing director Liz Dallimore said:

This is extremely encouraging data showing a potential new indication for ARG-007. It is well recognised that Abeta aggregation in the brain plays a key role in initiating Alzheimer's Disease, and therefore a safe therapeutic drug that can reduce Abeta aggregation is a huge opportunity.

We look forward to continuing to progress this exciting opportunity into further animal studies.

Argenica noted that the global Alzheimer's Disease therapeutics market size was valued at some US$4 billion in 2021. That's expected to increase at a compound annual growth rate (CAGR) of 16.2% from 2022 to 2030.

Argenica Therapeutics share price snapshot

Today's big leap has put the Argenica Therapeutics share price back in the green for 2023, up 16%. As you can see in the chart below, the ASX biotech stock remains down 28% over the past 12 months.

Should you invest $1,000 in Allkem right now?

Before you buy Allkem shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Allkem wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Two doctors wearing white coats look closely at a medical imaging x-ray as the share prices of ASX 200 healthcare shares improve in FY23
Healthcare Shares

Pro Medicus shares climb 33% in less than a month, have I missed the dip?

Pro Medicus shares have soared. Is it the right time to invest?

Read more »

Man with rocket wings which have flames coming out of them.
Share Gainers

Guess which ASX All Ords share just rocketed 19% on BIG news

Investors are sending this ASX All Ords share flying on Monday. But why?

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Healthcare Shares

Why is this ASX All Ords stock surging 14% today?

This stock is starting the week strongly. But why? Let's find out.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Healthcare Shares

Guess which ASX All Ords stock is rocketing 58% on big US news

What is getting investors excited today? Let's find out.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 reasons to buy this quality ASX 200 healthcare share today

A leading expert expects this outperforming ASX 200 healthcare share will keep running hot.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Brokers tip 4 ASX 200 healthcare shares to buy now

Healthcare is a defensive sector that can provide useful cover for investors when the market is volatile.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

How Trump's tariffs have created 'upside potential' for CSL shares

A leading expert says CSL shares are now looking ‘cheap’.

Read more »

Shot of a young scientist looking stressed out while working on a computer in a lab.
Healthcare Shares

Telix shares crash 8% on US FDA blow

This high-flying stock has been hit with some bad news.

Read more »